Peter Langmuir, MD
Incyte Corporation · AstraZeneca
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Peter Langmuir, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04071366 · A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyIncyte Corporation · completed · Cytokine Release Syndrome · study director
- Ph2NCT03822117 · Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)Incyte Corporation · terminated · Solid Tumor Malignancy · study director
- Ph3NCT03656536 · A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaIncyte Corporation · terminated · Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma · study director
- Ph1NCT03424122 · INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)Incyte Corporation · completed · B-cell Lymphoma · study director
- Ph2NCT02955940 · An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibIncyte Corporation · active not recruiting · Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer · study director
- Ph1/Ph2NCT02760485 · A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaIncyte Corporation · completed · Lymphoma · study director
- Ph2NCT02456675 · INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaIncyte Corporation · terminated · Refractory Hodgkin Lymphoma, Recurrent Adult Hodgkin's Lymphoma · study director
- Ph1NCT01905813 · Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesIncyte Corporation · completed · B-cell Malignancies · study director
- Ph2NCT01348490 · Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)Incyte Corporation · completed · MPN (Myeloproliferative Neoplasms) · study director
- Ph1NCT00937664 · Safety and Tolerability Study of AZD7762 in Combination With GemcitabineAstraZeneca · terminated · Cancer, Solid Tumors, Advanced Solid Malignancies · study director
- Ph1NCT00473616 · Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and IrinotecanAstraZeneca · terminated · Advanced Solid Tumors, Cancer, Advanced Solid Malignancies · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.